NASDAQ
76.06USD
-0.45 (-0.59%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.8B
P/E
—
EPS
—
Beta
0.09
52W range
32-82.94
Day range
75.53–77.81
Open
77.64
Prev close
76.51
Volume
219.8K
Avg volume
771.8K
Dividend
0.00
IPO
2018-05-24
https://www.zacks.com/stock/news/2961745/kiniksa-pharmaceuticals-international-plc-knsa-q2-earnings-match-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2961745 · 7/28/2026+0.60
https://www.defenseworld.net/2026/07/26/kiniksa-pharmaceuticals-international-knsa-projected-to-announce-quarterly-earnings-on-tuesday.html · 7/26/2026+0.60
https://seekingalpha.com/article/4913592-kiniksa-pharmaceuticals-international-plc-knsa-presents-at-goldman-sachs-47th-annual-global · 6/10/2026+0.10
https://www.benzinga.com/trading-ideas/long-ideas/26/04/51932465/top-3-health-care-stocks-that-could-lead-to-your-biggest-gains-this-month · 4/21/2026+0.60
https://www.investors.com/news/ai-fueled-trio-among-top-five-stocks-near-buy-points/ · 4/4/2026
https://seekingalpha.com/article/4862399-kiniksa-arcalyst-is-the-engine-but-kpl-387-is-the-accelerator · 1/24/2026+0.90
https://www.globenewswire.com/news-release/2025/10/17/3168566/0/en/Kiniksa-Pharmaceuticals-Announces-U-S-Orphan-Drug-Designation-for-KPL-387-for-the-Treatment-of-Pericarditis.html · 10/17/2025+0.80
https://www.zacks.com/stock/news/2768320/wall-street-analysts-think-kiniksa-pharmaceuticals-international-plc-knsa-could-surge-29-3-read-this-before-placing-a-bet?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2768320 · 10/14/2025+0.60
https://www.zacks.com/stock/news/2729673/kiniksa-pharmaceuticals-international-plc-knsa-is-a-great-choice-for-trend-investors-here-s-why?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|recent_price_strength_screen-2729673 · 8/18/2025+1.00
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
